Arthritis Rheumatol: Tosili zuma anti-VS Cardiovascular Safety in Rheumatoid Arthritis.

The purpose of this study was to assess the risk of major adverse cardiovascular events (MACE) in patients treated with rheumatoid arthritis (RA) treated with tumor necrosis factor inhibitor etanrose.
this random, open-label, parallel group of patients who responded insufficiently to anti-rheumatic drugs with a change in conventional synthesis and had at least one cardiovascular (CV) risk factor, active seropositive RA (n - 3,080) patients.
1:1 randomly assigned patients to receive 8 mg/kg/month of open label Tosili bead singtag or 50 mg/week of Itansip.
followed up an average of 3.2 years for all patients. The main end point of
is to compare the time when MACE first occurs.
the test was driven by the exclusion of the Tosili Pearl monophonic group compared to the Inasip group, MACE's relative risk ratio was 1.8 or higher.
results showed that by the fourth week of treatment, serum LDL cholesterol, HDL cholesterol and triglyceride levels were 11.1%, 5.7% and 13.6% higher than those receiving Tosili zuma, respectively, compared to patients receiving Itanrup (P 0.001).
during the follow-up period, 83 cases of MACE occurred in the Tosili Zhu mono-antigroup, while 78 cases of MACE occurred in the heceps.
the estimated risk ratio of MACE in the Tosley Beads group relative to the Itanrip group is 1.05 (95% confidence interval 0.77-1.43).
sensitivity analysis and the results of population analysis in treatment are similar.
adverse events occurred more frequently in the tossizumab group, including severe infections and gastrointestinal perforation.
, the results provide us with insight into the CV safety of Tosili beads monotoriny compared to Itansip, and exclude the risk of MACE in patients with Tosili-Bead monoto-statin therapy at 1.43 or higher.
this result should be explained in combination with the clinical efficacy and non-CV safety of Tosilizumab.
.